866-997-4948(US-Canada Toll Free)

Acromegaly - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 73 Pages


Global Markets Directs, \'Acromegaly Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acromegaly. Acromegaly Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Acromegaly.
  • A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acromegaly pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Acromegaly.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acromegaly Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Acromegaly 8
Acromegaly Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Acromegaly Therapeutics - Products under Development by Companies 15
Companies Involved in Acromegaly Therapeutics Development 16
Merck & Co., Inc. 16
Novartis AG 17
Antisense Therapeutics Limited 18
Paladin Labs Inc. 19
Asterion Ltd 20
Camurus AB 21
Syntaxin Ltd 22
GP Pharm, S.A. 23
Aegis Therapeutics, LLC 24
Peptron, Inc. 25
Q Chip Ltd. 26
Crinetics Pharmaceuticals, Inc. 27
Acromegaly - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ATL-1103 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SXN-101959 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DG-3173 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
octreotide acetate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
octreotide acetate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GH Antagonists - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
octreotide acetate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
octreotide acetate LAR - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
FP-002 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
L-054522 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pasireotide LAR - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pasireotide LAR - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Somatostatin Agonists - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
octreotide SR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
octreotide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Acromegaly Therapeutics - Drug Profile Updates 54
Acromegaly Therapeutics - Discontinued Products 61
Acromegaly Therapeutics - Dormant Products 62
Acromegaly - Product Development Milestones 63
Featured News & Press Releases 63
Aug 02, 2013: Antisense Therapeutics Provides ATL1103 Phase II Trial Update 63
Jun 17, 2013: Ipsen Announces Clinically Relevant Results In Phase III PRIMARYS Study With Somatuline Autogel In Acromegaly Patients 64
Jun 14, 2013: Antisense Therapeutics Reports Positive New Animal Data On ATL1103 For Treatment Of Acromegaly 65
Apr 10, 2013: Antisense Therapeutics Commences Dosing Of Patients For Phase II Clinical Trial Of ATL1103 In Acromegaly 66
Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly 67
Mar 22, 2013: Antisense Therapeutics Announces Presentation Of Phase I Study Data On ATL1103 At Acromegaly Conference 67
Jan 25, 2013: Antisense Therapeutics Initiates Phase II Clinical Trial Of ATL1103 In Acromegaly 68
Jan 17, 2013: Teijin Pharma Launches Ipsen\'s Somatuline Subcutaneous Injection For Treatment Of Acromegaly And Pituitary Gigantism In Japan 69
Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim 70
Nov 26, 2012: Aspireo Pharma Announces EMA\'s Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim 70

Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Table


Number of Products Under Development for Acromegaly, H2 2013 8
Products under Development for Acromegaly - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Merck & Co., Inc., H2 2013 16
Novartis AG, H2 2013 17
Antisense Therapeutics Limited, H2 2013 18
Paladin Labs Inc., H2 2013 19
Asterion Ltd, H2 2013 20
Camurus AB, H2 2013 21
Syntaxin Ltd, H2 2013 22
GP Pharm, S.A., H2 2013 23
Aegis Therapeutics, LLC, H2 2013 24
Peptron, Inc., H2 2013 25
Q Chip Ltd., H2 2013 26
Crinetics Pharmaceuticals, Inc., H2 2013 27
Assessment by Monotherapy Products, H2 2013 28
Assessment by Stage and Route of Administration, H2 2013 30
Assessment by Stage and Molecule Type, H2 2013 32
Acromegaly Therapeutics - Drug Profile Updates 54
Acromegaly Therapeutics - Discontinued Products 61
Acromegaly Therapeutics - Dormant Products 62

List of Chart


Number of Products under Development for Acromegaly, H2 2013 8
Products under Development for Acromegaly - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 28
Assessment by Route of Administration, H2 2013 29
Assessment by Stage and Route of Administration, H2 2013 30
Assessment by Molecule Type, H2 2013 31
Assessment by Stage and Molecule Type, H2 2013 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *